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CASE PRESENTATION
A 44-year-old African-American woman was evaluated in
our clinic for hypertension and renal insufficiency. She had
been diagnosed with hypertension 5 years earlier, and
had recently been found to have an increased serum
creatinine and more difficult to control blood pressure.
After clinical evaluation, the renal disease was determined
to be, most probably, a result of hypertensive
nephrosclerosis. Her past medical history was otherwise
unremarkable. Medications included atenolol 50 mg twice
daily, valsartan 160 mg daily, hydrochlorothiazide 25 mg
daily, and amlodipine 5 mg daily. The patient did not
smoke or consume excessive alcohol; she worked as a
secretary and has one daughter. There was a strong family
history of hypertension. Review of systems was notable
for fatigue and reduced libido. Physical examination
revealed blood pressure 150/100 mm Hg and moderate
obesity, but was otherwise unremarkable. She had a
serum creatinine of 1.5 mg per 100 ml, hemoglobin (Hb)
10 g per 100 ml, with an estimated glomerular filtration
rate of 42 ml/min. Her urinalysis was notable for
trace protein and a bland sediment. The urine spot
protein-to-creatinine ratio was 0.34.
The patient was educated about chronic kidney
disease, hypertension, and diet. Hydrochlorothiazide
was discontinued, and furosemide 40 mg twice daily
was started. Blood pressure improved to 135/90 mm Hg,
at which time the dose of amlodipine was increased
to 10 mg daily. Subsequently erythropoietin treatment
was initiated once blood pressure was controlled.
At this time, iron indices were serum ferritin 81 ng/ml
and transferrin saturation 29%. The patient consented to
take part in the CHOIR (Correction of Hemoglobin and
Outcomes in Renal Insufficiency) study, an open label
trial of weekly epoetin alfa treatment to raise Hb
to a target of either 11.3 or 13.5 g per 100 ml.1
The patient was randomized to the higher Hb target
group. Treatment was initiated with epoetin alfa
10,000 U/week in the month of April in 2003. The initial
response was brisk, with Hb increasing from 9.8 to
12.3 g per 100 ml (Figure 1). At that point, responsiveness
waned and Hb did not reach the target. The dose of epoetin
alfa was raised per protocol to 20,000 U/week (Figure 1). In
addition, the patient was found to be iron deficient.
Intravenous sodium ferric gluconate was administered
at a dose of 250 mg for 4 weekly infusions. Iron indices
improved and Hb rose to the target for approximately
8 weeks. Iron deficiency, however, redeveloped and Hb
levels fell again to remain consistently below the target
level. Renal function remained stable. Despite repeated
intravenous iron treatment, iron deficiency persisted. The
patient had been having excessively heavy menstrual
flows, which she noted had been present for many
months, and was advised to see a gynecologist. After
several delays, gynecology evaluation was performed, and
a diagnosis of excessive menstrual blood loss due to
uterine leiomyomas (fibroids) was made. The patient was
withdrawn from participation in the CHOIR study, but
treatment with epoetin alfa at 20,000–40,000 U/week was
continued. Treatment was initiated with the
gonadotropin-releasing hormone agonist, leuprolide
acetate. Within 2 months, the patient developed
amenorrhea with a substantially reduced uterine size.
With amenorrhea and oral iron therapy, iron indices
improved and Hb rose to greater than 14 g per 100 ml.
The dose of epoetin alfa was reduced to 10,000 U/week.
CLINICAL DIAGNOSIS
Uterine leiomyomas causing menorrhagia, iron deficiency,
and epoetin hyporesponsiveness.
CLINICAL FOLLOW-UP
After discontinuation of leuprolide acetate, menorrhagia
recurred, as did iron deficiency. The patient’s anemic
condition again became difficult to treat, with Hb falling
progressively to less than 10 g per 100 ml. A decision was
made to proceed to hysterectomy.
DISCUSSION
This case illustrates some of the difficulties encountered
in treating anemia of kidney disease. Use of erythropoiesis-
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stimulating agents (ESAs) has been a great advance, and has
led to marked improvement in the quality of life of patients
with chronic kidney disease (CKD).1–3 However, a number of
factors may interfere with the effectiveness of treatment, and
the clinician must be savvy in his/her detection and treatment
of the same. Iron deficiency is a common cause of ESA
hyporesponse. In hemodialysis, procedural blood loss
frequently causes iron deficiency, and routine intravenous
iron treatment is often necessary. In contrast, in non-dialysis
CKD, the cause of iron deficiency may require investigation,
and reflexive intravenous iron treatment may delay the
recognition of clinically relevant conditions.
The dynamics of erythropoiesis in CKD reflect a relative
deficiency of erythropoietin,4 so that an imbalance occurs.
Erythrocytes lost to senescence are not sufficiently replaced
until a new steady state is reached, at a lower level of Hb.
Treatment with ESAs corrects the problem, allowing for the
attainment of a therapeutic target of Hb. The stimulation
of erythropoiesis by ESAs must be adequately supported
by sufficient iron stores or iron-deficient erythropoiesis will
develop and the response to ESAs will diminish.5 Higher the
target Hb level, greater the demand for iron.
The patient reported in this case was a subject in the
CHOIR study, a trial comparing two different target levels of
Hb, 11.3 and 13.5 g per 100 ml. The patient was randomized
into the higher target group. At the time when she was part
of the study, the prevailing National Kidney Foundation
Kidney Disease Outcomes Quality Initiative target Hb in the
United States of America was 11–12 g per 100 ml. The relative
increase in Hb from typical target levels to the near-normal
Hb target in the higher Hb group required substantial
erythropoietic intervention. This is evidenced by the more
than doubling of the mean dose of epoetin alfa in the higher
Hb group.6 Data on iron parameters are not provided in the
study report, but it is clear that using ESA treatment to
achieve near-normal Hb levels requires a much greater supply
of iron. A previous study of Hb normalization, performed in
hemodialysis patients, found a far greater need for intrave-
nous iron therapy in the high Hb target group.7 Therefore,
the development of iron deficiency as the Hb level increased
in this patient was not immediately surprising.
Knowledge regarding iron deficiency in CKD is mainly
derived from studies in hemodialysis. Less is known
regarding the iron status in non-dialysis CKD. Iron deficiency
is remarkably common in end-stage renal disease patients on
hemodialysis.8 A variety of factors probably contribute,
including treatment-related blood loss, frequent blood
sampling for laboratory testing, accidental and surgical
blood loss, and the increased demand for iron induced by
ESA therapy.9 In non-dialysis CKD, iron deficiency might
be expected to occur less frequently, as blood loss from
hemodialysis is not present and drawing of blood for testing
is probably less frequent. However, a recent study suggested
that iron deficiency may be much more common than
previously thought.10 Gotloib et al. studied 47 consecutive
patients with CKD and Hb o12 g per 100 ml, performing
sternal bone marrow biopsies in all. Remarkably, 46 of the
47 patients had no stainable bone marrow iron; consistent
with severe iron deficiency.10 If these findings were to be
confirmed by others then it would suggest that for reasons
that are not immediately clear, iron deficiency is almost
universal in anemic patients with CKD.
The development of iron deficiency during ESA treatment
is so common an occurrence that clinicians may occasionally
make the mistake of automatically treating it with intra-
venous iron without considering the source of blood/
iron loss. In many cases, this practice may be harmless, as
iron deficiency may simply be a result of the accelerated
erythropoiesis driven by ESA treatment. However, in some
cases, the iron deficiency may reflect a serious occult disease
process such as colon cancer. Even in hemodialysis, where
blood loss and iron deficiency are routine, a prudent clinician
should consider the cause of iron deficiency and not
reflexively treat with intravenous iron.
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Figure 1 | Patient’s Hgb, iron status and treatment over the period in question.
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This patient’s iron deficiency became apparent to her
clinicians when her response to epoetin alfa diminished. After
an initial brisk increase in Hb, the level plateaued in the range
of 12–13 g per 100 ml, which was below the 13.5 g per 100 ml
study target. At that time, serum ferritin was 21 ng/ml
and transferrin saturation 11%, clearly indicative of iron
deficiency. The patient was treated with intravenous iron,
and experienced a transient increase in iron indices. The Hb
level rose to the target for a 3-month period, but iron
deficiency redeveloped. A second course of intravenous
iron was less successful, with persistent iron deficiency and
epoetin hyporesponsiveness. At this time, the patient revealed
that she had been experiencing very heavy menstrual flows.
The blood loss was, therefore, not only not occult but should
also have been readily apparent from history.
Menorrhagia may occasionally cause iron deficiency in
CKD, although menstruation may be interrupted when
kidney disease is present. The knowledge in this area comes
mainly from studies of women on hemodialysis. Holley and
colleagues studied 76 women less than 55 years of age on
hemodialysis. Surprisingly, despite the advanced stage of
kidney disease, they found 42% to still menstruate.11 Normal
menstruation is probably considerably more frequent in non-
dialysis CKD, but little has been published on this subject.
The impact of continued menstruation on the management
of anemia in CKD, both in terms of ESA treatment and iron
supplementation, is unclear. As blood loss from menstrua-
tion could potentially affect the efficacy of anemia therapy,
women under 55 years should be directly questioned
about their menstrual characteristics before initiating ESA
treatment.
In this patient, uterine fibroids were the cause of heavy
menstruation and iron deficiency. These benign tumors are
a leading cause for hysterectomy in younger women.12
Abnormal uterine bleeding is the most common symptom
of uterine fibroids (pain is also frequently a problem).13,14 In
a study of 910 pre-menopausal women, the risk of heavy
bleeding was increased up to 2.5-fold among women with
fibroids.15 Tumors are most likely to cause excessive bleeding
if located in the submucosal position.16 When menstrual
bleeding is heavy, the risk for iron deficiency is greatly
increased.12 The demographics and clinical characteristics of
uterine fibroids suggest that they may be common among
women with CKD and might have an impact on ESA therapy.
Treatment of uterine fibroid tumors is typically based on
the degree of symptoms present. In this patient, treatment
with the gonadotropin-releasing hormone agonist leuprolide
acetate led to a substantial improvement in fibroid size and
iron indices. The gonadotropin-releasing hormone agonists
cause a desensitization to gonadotrophs, resulting in a
hypogonadal, menopause-like state. Fibroids tend to regress
substantially with treatment, accompanied with improve-
ment in symptoms.17 Development of side effects and risk for
osteoporosis often limit the medical treatment of fibroids,
making surgery necessary. After discontinuation of the drug,
this patient’s symptoms recurred rapidly, as is often the case
in medical treatment of uterine fibroids. Serum ferritin
decreased again, to 19 ng/ml, and transferrin saturation was
10%. Severe anemia was again present, with Hb decreasing
to 9.8 g per 100 ml. A decision was made to proceed to
hysterectomy.
POSTSCRIPT
Two years after discontinuing leuprolide acetate treatment,
the patient had still not followed-up with her gynecologist for
surgery. Yet, despite this, there was a dramatic improvement
in anemia, with Hb gradually increasing to 13.5 g per 100 ml.
Moreover, iron deficiency resolved, with serum ferritin
increasing to 238 ng/ml and transferrin saturation to 22.5%.
Stable iron status continued even without iron supplementa-
tion. We invite readers to submit their explanation regarding
the apparently corrected iron deficiency and anemia in this
patient.
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